Related Experiment Video

Updated: Apr 23, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.8K

Making sense of dual HER2-targeting in early breast cancer?

Lisa A Carey1, William Barry2

  • 1Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC (LAC); Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA (WB). lisa_carey@med.unc.edu.

Journal of the National Cancer Institute
|September 17, 2014
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors
11:52

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

10.0K
Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

903

Related Experiment Videos

Last Updated: Apr 23, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.8K
Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors
11:52

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

10.0K
Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

903

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K

Articles linked to this work by shared authors, journal, and citation graph.

Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Integrative Transcriptional and Chromatin Analyses Reveal Enhancer-Mediated Regulatory Programs Driving Breast Cancer Metastasis.

Molecular cancer research : MCR·2026

Molecular evaluation of residual disease following neoadjuvant chemotherapy in triple-negative breast cancer CALGB 40603 (Alliance).

The Journal of clinical investigation·2026

Kinase Plasticity with Vandetanib Treatment Enhances Sensitivity to Tamoxifen in Estrogen Receptor Positive Breast Cancer.

Molecular cancer therapeutics·2026

Tucatinib in Combination With Trastuzumab Deruxtecan in Patients With Previously Treated HER2+ Unresectable Locally Advanced or Metastatic Breast Cancer: An Open-Label Phase 2 Study.

Clinical breast cancer·2026

The MEK inhibitor trametinib incurs mitochondrial injury and induces innate immune responses in the mouse heart.

Science advances·2026

Per- and polyfluoroalkyl substances levels other than PFOS, PFOA, or PFHxS and liver cancer risk: a nested case-control analysis.

Journal of the National Cancer Institute·2026

Effectiveness of an eHealth intervention to improve quality of life in long-term breast cancer survivors: a 9-month randomized controlled trial.

Journal of the National Cancer Institute·2026

Antidepressant and antipsychotic prescriptions among 21 605 English survivors of childhood cancer: a population-based cohort.

Journal of the National Cancer Institute·2026

Recent advancements in gynecologic cancer research: a SPORE investigators meeting report.

Journal of the National Cancer Institute·2026

Breast cancer overdiagnosis in mammography trials-separating signal from noise: a meta-analysis.

Journal of the National Cancer Institute·2026

Expansion of the world health organization (WHO) gastric neuroendocrine tumor classification: introducing types 4 and 5.

Journal of the National Cancer Institute·2026

ANAPC7 promotes triple-negative breast cancer progression through ANAPC2-dependent degradation of PCGF2 and activation of STAT3.

Molecular cancer research : MCR·2026

pH-Responsive drug delivery system for tumor therapy.

Nanoscale·2026

Spatiotemporally controlled degradation of CDK6 via light-triggered ROS generation: uncovering the proximity effect-mediated dual target depletion.

Organic & biomolecular chemistry·2026

Inducible IL-12 or IL-18 secreting CAR T cells targeting the glyco-antigen CD176 exhibit potent activity against non-small cell lung cancer in preclinical models.

Cancer immunology research·2026

Targeting RAS for Pancreatic Cancer Interception.

Cancer discovery·2026

Comprehensive Genomic Profiling Beyond Driver Testing in Non-Squamous Non-Small Cell Lung Cancer With Known Drivers.

Cancer science·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us